Systemic Anti-cancer Treatment in Malignant Ovarian Germ Cell Tumours (MOGCTs): Current Management and Promising Approaches

Overview

Journal Ann Transl Med

Publisher AME Publishing Company

Date 2021 Jan 25

PMID 33490225

Citations 13

Authors

Mario Uccello

Stergios Boussios

Eleftherios P Samartzis

Michele Moschetta

Affiliations

Soon will be listed here.

Abstract

Malignant ovarian germ cell tumours (MOGCTs) are rare. Unlike epithelial ovarian cancer, MOGCTs typically occur in girls and young women. Fertility-sparing surgery and platinum-based chemotherapy remain the standard of care, providing high chance of cure at all stages. Given the lack of high-quality studies in this field, current practice guidelines recommend chemotherapy regimens adopted in testicular germ cell tumours. However, platinum-resistant/refractory MOGCTs retain a worse prognosis in comparison with their male counterpart. Herein, we focus on current systemic anti-cancer treatment options in MOGCTs and promising approaches. Future studies enrolling exclusively female participants or germ cell tumour trials allowing participation of MOGCT patients are strongly recommended in order to improve evidence on existing management and develop novel strategies.

Citing Articles

Investigating the role of exosomal long non-coding RNAs in drug resistance within female reproductive system cancers.

Shirani N, Abdi N, Chehelgerdi M, Yaghoobi H, Chehelgerdi M Front Cell Dev Biol. 2025; 13:1485422.

PMID: 39925739 PMC: 11802832. DOI: 10.3389/fcell.2025.1485422.

Revitalizing premature ovarian failure: quercetin counteracts imatinib-induced apoptosis via the PI3K/AKT signaling pathway based on network pharmacology.

Ji M, Weng S, Li X, Xiao Q, Tong Y, Zhou Y Naunyn Schmiedebergs Arch Pharmacol. 2024; 398(1):833-842.

PMID: 39073414 DOI: 10.1007/s00210-024-03293-3.

A Comprehensive Review of Current Trends in the Diagnosis and Treatment of Ovarian Germ Cell Tumors.

Dantkale K, Agrawal M Cureus. 2024; 16(1):e52650.

PMID: 38380211 PMC: 10877227. DOI: 10.7759/cureus.52650.

Development and Perspectives: Multifunctional Nucleic Acid Nanomedicines for Treatment of Gynecological Cancers.

Korzun T, Moses A, Diba P, Sattler A, Olson B, Taratula O Small. 2023; 20(41):e2301776.

PMID: 37518857 PMC: 10827528. DOI: 10.1002/smll.202301776.

Clinical Challenges in the Management of Malignant Ovarian Germ Cell Tumours.

Saani I, Raj N, Sood R, Ansari S, Mandviwala H, Sanchez E Int J Environ Res Public Health. 2023; 20(12).

PMID: 37372675 PMC: 10298722. DOI: 10.3390/ijerph20126089.

References

Boussios S, Attygalle A, Hazell S, Moschetta M, McLachlan J, Okines A . Malignant Ovarian Germ Cell Tumors in Postmenopausal Patients: The Royal Marsden Experience and Literature Review. Anticancer Res. 2015; 35(12):6713-22. View

Alifrangis C, Agarwal R, Short D, Fisher R, Sebire N, Harvey R . EMA/CO for high-risk gestational trophoblastic neoplasia: good outcomes with induction low-dose etoposide-cisplatin and genetic analysis. J Clin Oncol. 2012; 31(2):280-6. DOI: 10.1200/JCO.2012.43.1817. View

Kraggerud S, Hoei-Hansen C, Alagaratnam S, Skotheim R, Abeler V, Rajpert-De Meyts E . Molecular characteristics of malignant ovarian germ cell tumors and comparison with testicular counterparts: implications for pathogenesis. Endocr Rev. 2013; 34(3):339-76. PMC: 3787935. DOI: 10.1210/er.2012-1045. View

Fenner M, Beutel G, Grunwald V . Targeted therapies for patients with germ cell tumors. Expert Opin Investig Drugs. 2008; 17(4):511-22. DOI: 10.1517/13543784.17.4.511. View

June C, OConnor R, Kawalekar O, Ghassemi S, Milone M . CAR T cell immunotherapy for human cancer. Science. 2018; 359(6382):1361-1365. DOI: 10.1126/science.aar6711. View

Rashdan S, Einhorn L . Salvage Therapy for Patients With Germ Cell Tumor. J Oncol Pract. 2016; 12(5):437-43. DOI: 10.1200/JOP.2016.011411. View

Zagame L, Pautier P, Duvillard P, Castaigne D, Patte C, Lhomme C . Growing teratoma syndrome after ovarian germ cell tumors. Obstet Gynecol. 2006; 108(3 Pt 1):509-14. DOI: 10.1097/01.AOG.0000231686.94924.41. View

Boussios S, Moschetta M, Zarkavelis G, Papadaki A, Kefas A, Tatsi K . Ovarian sex-cord stromal tumours and small cell tumours: Pathological, genetic and management aspects. Crit Rev Oncol Hematol. 2017; 120:43-51. DOI: 10.1016/j.critrevonc.2017.10.007. View

Boussios S, Zarkavelis G, Seraj E, Zerdes I, Tatsi K, Pentheroudakis G . Non-epithelial Ovarian Cancer: Elucidating Uncommon Gynaecological Malignancies. Anticancer Res. 2016; 36(10):5031-5042. DOI: 10.21873/anticanres.11072. View

10.

Lawrence N, Chan H, Toner G, Stockler M, Martin A, Yip S . Protocol for the P3BEP trial (ANZUP 1302): an international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours. BMC Cancer. 2018; 18(1):854. PMC: 6114870. DOI: 10.1186/s12885-018-4745-3. View

11.

Cossu-Rocca P, Jones T, Roth L, Eble J, Zheng W, Abdul Karim F . Cytokeratin and CD30 expression in dysgerminoma. Hum Pathol. 2006; 37(8):1015-21. DOI: 10.1016/j.humpath.2006.02.018. View

12.

Huddart R, Gabe R, Cafferty F, Pollock P, White J, Shamash J . A randomised phase 2 trial of intensive induction chemotherapy (CBOP/BEP) and standard BEP in poor-prognosis germ cell tumours (MRC TE23, CRUK 05/014, ISRCTN 53643604). Eur Urol. 2014; 67(3):534-43. PMC: 4410298. DOI: 10.1016/j.eururo.2014.06.034. View

13.

Semaan A, Haddad F, Eid R, Kourie H, Nemr E . Immunotherapy: last bullet in platinum refractory germ cell testicular cancer. Future Oncol. 2019; 15(5):533-541. DOI: 10.2217/fon-2018-0571. View

14.

Smith H, Berwick M, Verschraegen C, Wiggins C, Lansing L, Muller C . Incidence and survival rates for female malignant germ cell tumors. Obstet Gynecol. 2006; 107(5):1075-85. DOI: 10.1097/01.AOG.0000216004.22588.ce. View

15.

De Giorgi U, Casadei C, Bergamini A, Attademo L, Cormio G, Lorusso D . Therapeutic Challenges for Cisplatin-Resistant Ovarian Germ Cell Tumors. Cancers (Basel). 2019; 11(10). PMC: 6826947. DOI: 10.3390/cancers11101584. View

16.

Mangili G, Sigismondi C, Gadducci A, Cormio G, Scollo P, Tateo S . Outcome and risk factors for recurrence in malignant ovarian germ cell tumors: a MITO-9 retrospective study. Int J Gynecol Cancer. 2011; 21(8):1414-21. DOI: 10.1097/IGC.0b013e3182236582. View

17.

Simone C, Markham M, Dizon D . Chemotherapy in ovarian germ cell tumors: A systematic review. Gynecol Oncol. 2016; 141(3):602-607. DOI: 10.1016/j.ygyno.2016.02.007. View

18.

Hoei-Hansen C, Kraggerud S, Abeler V, Kaern J, Rajpert-De Meyts E, Lothe R . Ovarian dysgerminomas are characterised by frequent KIT mutations and abundant expression of pluripotency markers. Mol Cancer. 2007; 6:12. PMC: 1797189. DOI: 10.1186/1476-4598-6-12. View

19.

OSullivan J, Huddart R, Norman A, Nicholls J, Dearnaley D, Horwich A . Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. Ann Oncol. 2002; 14(1):91-6. DOI: 10.1093/annonc/mdg020. View

20.

Hong L, Chen Y, Smith C, Montgomery S, Vincent B, Dotti G . CD30-Redirected Chimeric Antigen Receptor T Cells Target CD30 and CD30 Embryonal Carcinoma via Antigen-Dependent and Fas/FasL Interactions. Cancer Immunol Res. 2018; 6(10):1274-1287. PMC: 7590161. DOI: 10.1158/2326-6066.CIR-18-0065. View